As a well-known HDAC inhibitor, SAHA can inhibit HDACI, HDAC IIa, and HDAC IIb, and has been approved for the treatment of refractory cutaneous T-cell lymphoma (CTCL) [98]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.